As the potential for an influenza pandemic has galvanized themedical community and the public into action, physicians andpatients alike have been heartened by the availability of effectiveantiviral drugs. The neuraminidase inhibitors provide valuabledefenses against pandemic and seasonal influenza, and physicianshave been flooded with requests from patients for personal suppliesof oseltamivir (Tamiflu). A benefit of having oseltamivir athome is that the sooner the drug is taken after the onset ofsymptoms, the better its clinical efficacy.1 And certainly,enabling ill people to stay home and out of waiting rooms andpharmacies should limit the . . . [Full Text of this Article]
Source Information
Dr. Moscona is a professor in the Departments of Pediatrics and Microbiology and Immunology at Weill Medical College of Cornell University, New York.
An interview with Dr. Moscona can be heard at www.nejm.org.
This article has been cited by other articles:
Moscona, A., McKimm-Breschkin, J.
(2007). News About Influenza B Drug Resistance That Cannot Be Ignored. JAMA
297: 1492-1493
[Full Text]
Thomas, J. K., Noppenberger, J.
(2007). Avian influenza: A review. Am J Health Syst Pharm
64: 149-165
[Abstract][Full Text]
Weinstock, D. M., Zucotti, G.
(2006). Shift Shown in Influenza A Adamantane Resistance--Reply. JAMA
296: 1587-1587
[Full Text]
Gupta, R. K., Nguyen-Van-Tam, J. S., de Jong, M. D., Hien, T. T., Farrar, J.
(2006). Oseltamivir resistance in influenza A (H5N1) infection.. NEJM
354: 1423-1424
[Full Text]
(2006). Two More Cases of Oseltamivir-Resistant Avian Influenza. JWatch Pediatrics
2006: 7-7
[Full Text]
Weinstock, D. M., Zuccotti, G.
(2006). Adamantane Resistance in Influenza A. JAMA
295: 934-936
[Full Text]
Gostin, L. O.
(2006). Medical Countermeasures for Pandemic Influenza: Ethics and the Law. JAMA
295: 554-556
[Full Text]
(2006). Two More Cases of Oseltamivir-Resistant Avian Influenza. JWatch General
2006: 2-2
[Full Text]
Interview
